Thus, the importance of JAK2 inhibition only became meaningful after inhibiting BCR-ABL, which helps propose the necessity for continuing TKI in conjunction with novel therapeutic agents for CML LSC eradication. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.